SHORTList
Retro Biosciences logo
Biotech/Pharma
HealthTech

Retro Biosciences

Biotech company targeting aging mechanisms

Redwood City· 5 roles

CORE INFO

$1.8B
Total Funding
Series A
Round
2021
Founded
~79
Team Size
Redwood City, California, USA
Headquarters

Retro Biosciences is a biotechnology company focused on developing therapies that target the biological processes of aging, aiming to extend healthy human lifespan by ten years. Their innovative research areas include cellular reprogramming and plasma-inspired interventions, attracting scientists dedicated to longevity and regenerative medicine.

  • Retro Biosciences achieved a pre-money valuation of $1.8 billion in their latest funding round led by 4P Capital.statnews.com
  • The company's Alzheimer's candidate, RTR242, has progressed to Phase I clinical trials, showing promising results without dose-limiting toxicities.statnews.com
  • TechCrunch reported on Retro Biosciences' ambitious fundraising efforts, highlighting their collaboration with OpenAI.techcrunch.com

WHY WE WOULD WORK AT RETRO BIOSCIENCES

Impactful Mission

Join a team dedicated to extending healthy human lifespan by ten years through innovative therapies targeting aging mechanisms.

Cutting-Edge Research

Contribute to groundbreaking projects like RTR242, an Alzheimer's candidate currently in Phase I clinical trials, showing promising results.

Collaborative Culture

Be part of a supportive environment that values kindness, rigor, and versatility, fostering rapid iteration and feedback.

Strong Funding Backing

Work for a company with a pre-money valuation of $1.8 billion, ensuring stability and resources for ambitious projects.

Advanced Technologies

Utilize state-of-the-art technologies like single-cell multi-omics and targeted delivery systems to develop transformative therapies.

Growth Opportunities

Engage in a dynamic field of longevity and regenerative medicine, maximizing your impact and career potential in a rapidly evolving industry.

MARKET AND TRACTION

KEY METRICS

✦ KEY METRIC
  • Total funding raised amounts to $1.8 billion, positioning Retro Biosciences as a significant player in the biotechnology sector.

  • The company has approximately 79 employees, reflecting a focused team dedicated to advancing longevity research.

  • Estimated annual revenue is $12.2 million, indicating a growing financial foundation as they develop their therapies.

    • GROWTH TACTICS

  • Retro Biosciences is leveraging innovative research areas such as cellular reprogramming and autophagy enhancement to create therapies targeting aging mechanisms.

  • The company has advanced its Alzheimer's candidate, RTR242, into Phase I clinical trials, which is a critical step in their product development pipeline.

  • They emphasize a culture of kindness, rigor, and versatility to attract top scientific talent in the field of longevity and regenerative medicine.

    • MARKET POSITION

  • Retro Biosciences aims to extend healthy human lifespan by ten years, positioning itself at the forefront of the longevity biotechnology market.

  • With a pre-money valuation of $1.8 billion as of May 2026, the company is recognized for its ambitious goals and innovative approaches to age-related diseases.

  • The focus on therapies for age-related diseases places Retro Biosciences in a unique niche within the broader healthcare and biotechnology industries.

    • TOTAL ADDRESSABLE MARKET

  • The market for longevity and age-related disease therapeutics is rapidly expanding, driven by an aging global population and increasing interest in healthspan extension.

  • Retro Biosciences targets a significant unmet need in the healthcare sector, as current treatments for age-related diseases are limited and often ineffective.

  • By focusing on the underlying mechanisms of aging, the company is positioned to capture a substantial share of this emerging market.

    • COMPETITIVE ADVANTAGE

  • Retro Biosciences utilizes advanced technologies such as single-cell multi-omics and targeted delivery systems, which enhance their research capabilities.

  • The company's collaboration with notable investors like Sam Altman and 4P Capital provides not only financial backing but also strategic insights into the biotech landscape.

  • Their commitment to rapid iteration and vertical integration allows for tighter feedback loops in research and development, giving them an edge over competitors.

    • PRODUCT AND TECH

    Cellular Reprogramming

    Retro Biosciences utilizes partial reprogramming techniques to rejuvenate cells and tissues, aiming to reverse age-related cellular decline and enhance overall health.

    Autophagy Enhancement

    The company develops therapies that improve the body's natural autophagy process, which is crucial for clearing out damaged cells and proteins, thereby promoting cellular health and longevity.

    Plasma-Inspired Interventions

    Retro Biosciences investigates factors found in youthful blood plasma that may help reverse aging effects, potentially leading to innovative treatments for age-related diseases.

    RTR242 Clinical Candidate

    RTR242 is Retro Biosciences' Alzheimer's candidate that has advanced into Phase I clinical trials, showing promising results without dose-limiting toxicities, highlighting the company's commitment to addressing age-related diseases.

    Advanced Technology Stack

    The company employs cutting-edge technologies such as single-cell multi-omics and targeted delivery systems to develop their therapies, enhancing the precision and effectiveness of their interventions.

    COMPANY CULTURE

    Values

  • Kindness is at the core of our interactions

  • Rigor in research and development processes

  • Versatility to adapt and innovate

  • Commitment to maximizing impact in longevity science

  • Integrity in all our endeavors

    • Operating Principles

  • Emphasis on speed and rapid iteration

  • Vertical integration to enhance feedback loops

  • Collaboration across disciplines to foster innovation

  • Focus on addressing age-related diseases through cutting-edge research

    • Benefits

  • Opportunity to contribute to groundbreaking longevity research

  • Supportive and inclusive work environment

  • Access to advanced technologies and resources

  • Potential for significant personal and professional growth

    • Learning & Growth

  • Continuous learning encouraged through workshops and seminars

  • Mentorship programs to support career development

  • Opportunities to collaborate with leading experts in biotechnology

  • Encouragement to explore new ideas and approaches in research

    • Team Cadence

  • Regular team meetings to align on goals and progress

  • Open communication channels for feedback and ideas

  • Agile project management to adapt to changing research needs

  • Celebrating milestones and achievements as a team

    • HIRING SIGNAL

    5
    Open roles on their careers page
    Snapshot via live ATS poll
    —
    Net new roles in the last 90 days
    Available once weekly history accrues
    90-Day VelocityV2 · BACKFILL
    Trend builds weekly as historical rows accrue
    By Function
    Breakdown of open roles
    Other · 1
    G&A · 1
    Operations · 2
    Engineering · 1
    Top Locations
    Where hiring is concentrated
    Remote-eligible postings counted separately
    Redwood City, CA
    5
    SourcesGreenhouseLeverAshbyWorkableSmartRecruitersRipplingRecruiteeFallback · Wellfound, YC Work-at-a-Startup, careers-page scrape

    KEY COMPANY ANNOUNCEMENTS

    Filter
    8 announcements · ranked by importance
    Jan 24, 2025FUNDINGRetro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan | TechCrunchtechcrunch.com
    May 22, 2026FUNDINGLongevity startup Retro Biosciences says latest fundraise values it at $1.8 billionstatnews.com
    Apr 7, 2022FUNDINGBioCentury - April 6 Quick Takes: Retro lands with $180M for multidisease preventionbiocentury.com
    Jun 20, 2026INTERVIEWJoe Betts-LaCroix on Retro, Reprogramming, and the First Real Longevity Drugs | Frameshifts Episode #13frameshifts.bio
    Apr 5, 2024FOUNDER PROFILEJoe Betts-LaCroix SM ’92 asks: What would you do with 10 extra years? - MIT EAPSeaps.mit.edu
    May 20, 2025CUSTOMER WINNew US$35m partnership to advance blood disorder therapies - Murdoch Children's Research Institutemcri.edu.au
    Jun 23, 2023ESSAYOur mission is to add 10 years to healthy human lifespanretro.bio
    Jan 1, 2022EXEC HIREWelcome Dr. Joseph Fraietta! A world-class immunologist, Dr. Fraietta has joined Retro’s Scientific Advisory Board. Together we will accelerate our T-cell research programs including reprogramming… | Retro Bioscienceslinkedin.com